Mancini M

References (6)

Title : Office Paper-Based Electrochemical Strips for Organophosphorus Pesticide Monitoring in Agricultural Soil - Cioffi_2021_Environ.Sci.Technol__
Author(s) : Cioffi A , Mancini M , Gioia V , Cinti S
Ref : Environ Sci Technol , : , 2021
Abstract : Although the use of pesticides has highlighted obvious advantages on agricultural yields, intensive and widespread pesticide use raises serious environmental and health concerns. In particular, organophosphate pesticides represent >40% of the totality used in the field of agriculture, and developing countries face the issue of agricultural poisoning, also due to scarce monitoring programs. In this work, a decentralized, miniaturized, sustainable, and portable paper-based electrochemical biosensor for the quantification of organophosphorus pesticides' level has been realized. The proposed approach highlights the use of a very common paper-based substrate, namely, office paper. Office paper offers several advantages due to its nature: it allows one to print conductive strips for electrochemical connection, loading bio-hybrid nanosized probes (Prussian blue, carbon black, and butyrylcholinesterase), evaluating pesticides and reducing waste disposal compared to plastic-based strips. The portable system has been characterized by a low detection limit of 1.3 ng/mL, and accordingly to total discovered pesticide contents in EU agricultural soils, up to ca. 3 microg/mL, it can offer a valuable tool for fast monitoring. To demonstrate its effectiveness, soil and fruit vegetables have been used to perform in situ quantification. Good recovery percentages between 90 and 110% have been achieved in different matrices, highlighting to be suitable for field measurements, and a good correlation has been obtained in comparison with LC-MS analysis.
ESTHER : Cioffi_2021_Environ.Sci.Technol__
PubMedSearch : Cioffi_2021_Environ.Sci.Technol__
PubMedID: 34165948

Title : Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease - Mancini_2019_Parkinsonism.Relat.Disord_69_40
Author(s) : Mancini M , Chung K , Zajack A , Martini DN , Ramsey K , Lapidus J , Horak FB , Nutt JG
Ref : Parkinsonism Relat Disord , 69 :40 , 2019
Abstract : INTRODUCTION: Degeneration of cholinergic systems may contribute to impairments of balance and gait in Parkinson's disease (PD) and phase 2 clinical trials have suggested that centrally acting cholinesterase inhibitors reduce falls. Here, we examined the effects of augmenting cholinergic neurotransmission on static and dynamic balance, indices of fall risk. METHODS: A single-site, randomized, double-blind, crossover trial examined the effect of donepezil in patients with PD. Forty-nine participants with idiopathic PD were randomized and 45 completed the trial. Each treatment period was 6 weeks with a 6-week washout between treatments. Donepezil in 2.5mg capsules, or identical appearing placebo capsules, was increased from two per day (5mg) to four capsules (10mg) after 3 weeks. The primary outcome measures were the range of the medio-lateral sway when standing (static balance) and the variability of the stride duration when walking (dynamic balance). A linear mixed model was used to investigate whether the change in outcomes between weeks 0 and 6 differed between phases. RESULTS: There were no significant differences in treatment effects between placebo and donepezil for medio-lateral sway range during quiet standing (p=0.28), nor in gait variability (p=0.31). None of the secondary outcome measures or exploratory analyses were significant although one secondary measure of static balance was increased by donepezil. CONCLUSIONS: Contrary to our hypothesis, cholinergic augmentation with donepezil at 10mg/day for 6 weeks did not affect measures of static or dynamic balance in people with PD. These results are compared with other phase 2 trials of cholinesterase inhibitors and considerations for future trials are discussed.
ESTHER : Mancini_2019_Parkinsonism.Relat.Disord_69_40
PubMedSearch : Mancini_2019_Parkinsonism.Relat.Disord_69_40
PubMedID: 31675664

Title : Dopamine, vesicular transporters, and dopamine receptor expression in rat major salivary glands - Tomassoni_2015_Am.J.Physiol.Regul.Integr.Comp.Physiol_309_R585
Author(s) : Tomassoni D , Traini E , Mancini M , Bramanti V , Mahdi SS , Amenta F
Ref : American Journal of Physiology Regul Integr Comp Physiol , 309 :R585 , 2015
Abstract : The localization of dopamine stores and the expression and localization of dopamine (DAT) and vesicular monoamine transporters (VMAT) type-1 and -2 and of dopamine D1-like and D2-like receptor subtypes were investigated in rat submandibular, sublingual, and parotid salivary glands by HPLC with electrochemical detection, as well as immunochemical and immunohistochemical techniques. Male Wistar rats of 2 mo of age were used. The highest dopamine levels were measured in the parotid gland, followed by the submandibular and sublingual glands. Western blot analysis revealed DAT, VMAT-1, VMAT-2, and dopamine receptors immunoreactivity in membrane preparations obtained from the three glands investigated. Immunostaining for dopamine and transporters was developed within striated ducts. Salivary glands processed for dopamine receptors immunohistochemistry developed an immunoreaction primarily in striated and excretory ducts. In the submandibular gland, acinar cells displayed strong immunoreactivity for the D2 receptor, while cells of the convoluted granular tubules were negative for both D1-like and D2-like receptors. Parotid glands acinar cells displayed the highest immunoreactivity for both D1 and D2 receptors compared with other salivary glands. The above localization of dopamine and dopaminergic markers investigated did not correspond closely with neuron-specific enolase (NSE) localization. This indicates that at least in part, catecholamine stores and dopaminergic markers are independent from glandular innervation. These findings suggest that rat major salivary glands express a dopaminergic system probably involved in salivary secretion. The stronger immunoreactivity for dopamine transporters and receptors in striated duct cells suggests that the dopaminergic system could regulate not only quality, but also volume and ionic concentration of saliva.
ESTHER : Tomassoni_2015_Am.J.Physiol.Regul.Integr.Comp.Physiol_309_R585
PubMedSearch : Tomassoni_2015_Am.J.Physiol.Regul.Integr.Comp.Physiol_309_R585
PubMedID: 26136535

Title : Aptamer to ErbB-2\/HER2 enhances degradation of the target and inhibits tumorigenic growth - Mahlknecht_2013_Proc.Natl.Acad.Sci.U.S.A_110_8170
Author(s) : Mahlknecht G , Maron R , Mancini M , Schechter B , Sela M , Yarden Y
Ref : Proc Natl Acad Sci U S A , 110 :8170 , 2013
Abstract : Aptamers, oligonucleotides able to avidly bind cellular targets, are emerging as promising therapeutic agents, analogous to monoclonal antibodies. We selected from a DNA library an aptamer specifically recognizing human epidermal growth factor receptor 2 (ErbB-2/HER2), a receptor tyrosine kinase, which is overexpressed in a variety of human cancers, including breast and gastric tumors. Treatment of human gastric cancer cells with a trimeric version (42 nucleotides) of the selected aptamer (14 nucleotides) resulted in reduced cell growth in vitro, but a monomeric version was ineffective. Likewise, when treated with the trimeric aptamer, animals bearing tumor xenografts of human gastric origin reflected reduced rates of tumor growth. The antitumor effect of the aptamer was nearly twofold stronger than that of a monoclonal anti-ErbB-2/HER2 antibody. Consistent with aptamer-induced intracellular degradation of ErbB-2/HER2, incubation of gastric cancer cells with the trimeric aptamer promoted translocation of ErbB-2/HER2 from the cell surface to cytoplasmic puncta. This translocation was associated with a lysosomal hydrolase-dependent clearance of the ErbB-2/HER2 protein from cell extracts. We conclude that targeting ErbB-2/HER2 with DNA aptamers might retard the tumorigenic growth of gastric cancer by means of accelerating lysosomal degradation of the oncoprotein. This work exemplifies the potential pharmacological utility of aptamers directed at cell surface proteins, and it highlights an endocytosis-mediated mechanism of tumor inhibition.
ESTHER : Mahlknecht_2013_Proc.Natl.Acad.Sci.U.S.A_110_8170
PubMedSearch : Mahlknecht_2013_Proc.Natl.Acad.Sci.U.S.A_110_8170
PubMedID: 23630281

Title : Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2\/ErbB-2 - Maron_2013_Proc.Natl.Acad.Sci.U.S.A_110_15389
Author(s) : Maron R , Schechter B , Mancini M , Mahlknecht G , Yarden Y , Sela M
Ref : Proc Natl Acad Sci U S A , 110 :15389 , 2013
Abstract : Due to intrinsic aggressiveness and lack of effective therapies, prognosis of pancreatic cancer remains dismal. Because the only molecular targeted drug approved for pancreatic ductal adenocarcinoma is a kinase inhibitor specific to the epidermal growth factor receptor (EGFR), and this receptor collaborates with another kinase, called HER2 (human EGF-receptor 2), we assumed that agents targeting EGFR and/or HER2 would effectively retard pancreatic ductal adenocarcinoma. Accordingly, two immunological strategies were tested in animal models: (i) two antibodies able to engage distinct epitopes of either EGFR or HER2 were separately combined, and (ii) pairs of one antibody to EGFR and another to HER2. Unlike the respective single monoclonal antibodies, which induced weak effects, both types of antibody combinations synergized in animals in terms of tumor inhibition. Immunological cooperation may not depend on receptor density, antigenic sites, or the presence of a mutant RAS protein. Nevertheless, both types of antibody combinations enhanced receptor degradation. Future efforts will examine the feasibility of each strategy and the potential of combining them to achieve sustained tumor inhibition.
ESTHER : Maron_2013_Proc.Natl.Acad.Sci.U.S.A_110_15389
PubMedSearch : Maron_2013_Proc.Natl.Acad.Sci.U.S.A_110_15389
PubMedID: 24003140

Title : Choline acetyltransferase and acetylcholinesterase in the hippocampus of aged rats: sensitivity to choline alphoscerate treatment - Amenta_1994_Mech.Ageing.Dev_74_47
Author(s) : Amenta F , Bronzetti E , Mancini M , Vega JA , Zaccheo D
Ref : Mech Ageing Dev , 74 :47 , 1994
Abstract : The influence of aging on the acetylcholine synthesising and the degrading enzymes choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) was studied in the hippocampus of male Wstar rats at 2 months (young), 12 months (adult) and 27 months (old) of age using biochemical, immunocytochemical and histochemical techniques. The influence of treatment for 6 months with a daily dose of 100 mg/kg of choline alphoscerate (L-alpha-glycerylphosphorylcholine) on the parameters examined was also investigated in old rats. Biochemical analysis of ChAT and AChE revealed the highest of the enzymatic activities in the hippocampus of adult rats and no significant differences between young and old animals. Immunocytochemical analysis of ChAT immunoreactivity revealed the highest immunostaining in adult rats followed in descending order by young then old animals. Histochemical evaluation of AChE reactivity revealed the highest expression in adult rats followed in descending order by old then young animals. Biochemical analysis of the effects of choline alphoscerate did not reveal any effect on ChAT activity and in increased expression of AChE activity. Moreover, the compound restored, in part, ChAT immunoreactivity in the hippocampus of old rats and increased the expression of AChE reactivity primarily in the CA3 sub field in old rats. The above results suggest that appropriate quantitative immunocytochemical and histochemical techniques may represent a useful tool for assessing age-dependent changes in cholinergic neurotransmission markers. The functional and pharmacological significance of the effects of choline alphoscerate on the expression of ChAT and AChE in the hippocampus of aged rats should be clarified in future studies.
ESTHER : Amenta_1994_Mech.Ageing.Dev_74_47
PubMedSearch : Amenta_1994_Mech.Ageing.Dev_74_47
PubMedID: 7934207